S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
S&P 500   4,273.53 (-1.47%)
DOW   33,618.88 (-1.14%)
QQQ   354.21 (-1.50%)
AAPL   171.96 (-2.34%)
MSFT   312.14 (-1.70%)
META   298.96 (-0.62%)
GOOGL   128.57 (-1.94%)
AMZN   125.98 (-4.03%)
TSLA   244.12 (-1.16%)
NVDA   419.11 (-0.74%)
NIO   8.40 (+0.60%)
BABA   85.88 (-1.54%)
AMD   95.96 (-1.46%)
T   15.02 (-0.27%)
F   12.44 (-1.11%)
MU   67.94 (-0.93%)
CGC   0.92 (-2.20%)
GE   109.94 (-1.59%)
DIS   80.04 (-1.20%)
AMC   7.92 (-2.82%)
PFE   32.37 (-1.85%)
PYPL   58.93 (+0.12%)
NFLX   379.25 (-1.44%)
NASDAQ:NURO

NeuroMetrix (NURO) Stock Forecast, Price & News

$0.64
0.00 (0.00%)
(As of 09/26/2023 ET)
Compare
Today's Range
$0.61
▼
$0.65
50-Day Range
$0.64
▼
$0.98
52-Week Range
$0.60
▼
$3.45
Volume
43,486 shs
Average Volume
65,890 shs
Market Capitalization
$5.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

NURO stock logo

About NeuroMetrix (NASDAQ:NURO) Stock

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NURO Price History

NURO Stock News Headlines

September 20, 2023 | americanbankingnews.com
NeuroMetrix (NASDAQ:NURO) Coverage Initiated by Analysts at StockNews.com
August 30, 2023 | finance.yahoo.com
NeuroMetrix to Present at the Emerging Growth Conference on September 6, 2023
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
August 28, 2023 | finance.yahoo.com
Is NeuroMetrix (NURO) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
July 27, 2023 | finanznachrichten.de
NeuroMetrix, Inc.: NeuroMetrix Reports Q2 2023 Business Highlights
July 27, 2023 | finance.yahoo.com
NeuroMetrix Reports Q2 2023 Business Highlights
July 20, 2023 | finance.yahoo.com
NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference Call
July 11, 2023 | finance.yahoo.com
NeuroMetrix Announces Sales Force Expansion for Quell Fibromyalgia
September 26, 2023 | Micro-Cap Stock Trader (Ad)
Unlock the treasure on Mount Olympus with this little-known mining stock.
Investor Find Lithium Gold and Crush the Bear Market with 32k Metric Tons
June 28, 2023 | finance.yahoo.com
Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes Patients
June 7, 2023 | finance.yahoo.com
Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical Study
May 31, 2023 | finance.yahoo.com
Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)
May 16, 2023 | bizjournals.com
Autonomous delivery vehicle startup Nuro is cutting staff and production to focus on R&D
May 3, 2023 | finance.yahoo.com
NeuroMetrix Reports Q1 2023 Financial Results
April 28, 2023 | finance.yahoo.com
NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call
March 21, 2023 | finance.yahoo.com
NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting
March 14, 2023 | thestreet.com
Why NeuroMetrix (NURO) Stock Is Soaring Today
February 25, 2023 | finance.yahoo.com
NeuroMetrix Full Year 2022 Earnings: US$0.62 loss per share (vs US$0.45 loss in FY 2021)
February 23, 2023 | finance.yahoo.com
NeuroMetrix Reports Q4 and Full Year 2022 Financial Results
February 16, 2023 | finance.yahoo.com
NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call
February 7, 2023 | thestreet.com
NeuroMetrix (NURO) Stock Gains After Launching Diabetes Test in Mexico
January 23, 2023 | finance.yahoo.com
NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy
December 11, 2022 | finance.yahoo.com
NeuroMetrix, Inc. (NURO) Stock Historical Prices & Data - Yahoo Finance
November 8, 2022 | finance.yahoo.com
NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting
November 3, 2022 | finance.yahoo.com
NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia
October 20, 2022 | benzinga.com
NeuroMetrix shares are trading lower after the company reported Q3 EPS and sales results were down year over year. - NeuroMetrix (NASDAQ:NURO) - Benzinga
October 20, 2022 | globenewswire.com
NeuroMetrix Reports Q3 2022 Financial Results - GlobeNewswire
See More Headlines
Receive NURO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter.

NURO Company Calendar

Last Earnings
7/27/2023
Today
9/26/2023
Next Earnings (Estimated)
10/19/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NURO
CUSIP
N/A
CIK
1289850
Web
www.neurometrix.com
Phone
(781) 890-9989
Fax
302-636-5454
Employees
27
Year Founded
1996

Profitability

EPS (Most Recent Fiscal Year)
($0.71)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,420,000.00
Net Margins
-75.17%
Pretax Margin
-75.17%
Return on Equity
-24.38%
Return on Assets
-22.75%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
18.42
Quick Ratio
17.11

Sales & Book Value

Annual Sales
$8.26 million
Price / Sales
0.64
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.01 per share
Price / Book
0.20

Miscellaneous

Outstanding Shares
8,590,000
Free Float
7,941,000
Market Cap
$5.25 million
Optionable
Not Optionable
Beta
2.28

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Shai N. Gozani M.D. (Age 58)
    Ph.D., Founder, Chairman, CEO, Pres & Sec.
    Comp: $437.82k
  • Mr. Thomas T. HigginsMr. Thomas T. Higgins (Age 71)
    Sr. VP, CFO & Treasurer
    Comp: $342.87k
  • Dr. Xuan Kong Ph.D.
    Chief Data Scientist
  • Ms. Susan M. Bell R.N.
    Sr. VP of Population Health & Value Based Care

Key Competitors

View All Competitors













NURO Stock - Frequently Asked Questions

How have NURO shares performed in 2023?

NeuroMetrix's stock was trading at $1.49 on January 1st, 2023. Since then, NURO shares have decreased by 59.0% and is now trading at $0.6116.
View the best growth stocks for 2023 here.

Are investors shorting NeuroMetrix?

NeuroMetrix saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 26,100 shares, an increase of 76.4% from the August 15th total of 14,800 shares. Based on an average daily volume of 79,100 shares, the days-to-cover ratio is presently 0.3 days.
View NeuroMetrix's Short Interest.

When is NeuroMetrix's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 19th 2023.
View our NURO earnings forecast.

How were NeuroMetrix's earnings last quarter?

NeuroMetrix, Inc. (NASDAQ:NURO) released its quarterly earnings results on Thursday, July, 27th. The medical device company reported ($0.19) EPS for the quarter. The medical device company earned $1.66 million during the quarter. NeuroMetrix had a negative net margin of 75.17% and a negative trailing twelve-month return on equity of 24.38%.

When did NeuroMetrix's stock split?

Shares of NeuroMetrix reverse split before market open on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

What is Shai N. Gozani's approval rating as NeuroMetrix's CEO?

10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeuroMetrix own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), ReWalk Robotics (RWLK), Aurora Cannabis (ACB), Advanced Micro Devices (AMD) and Vaxart (VXRT).

What is NeuroMetrix's stock symbol?

NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO."

How do I buy shares of NeuroMetrix?

Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeuroMetrix's stock price today?

One share of NURO stock can currently be purchased for approximately $0.61.

How much money does NeuroMetrix make?

NeuroMetrix (NASDAQ:NURO) has a market capitalization of $5.25 million and generates $8.26 million in revenue each year. The medical device company earns $-4,420,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

How can I contact NeuroMetrix?

NeuroMetrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The official website for the company is www.neurometrix.com. The medical device company can be reached via phone at (781) 890-9989, via email at neurometrix.ir@neurometrix.com, or via fax at 302-636-5454.

This page (NASDAQ:NURO) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -